Researchers have successfully developed a biomarker that will enable Parkinson’s disease to be rapidly and inexpensively diagnosed from blood serum samples.
Researchers at Kobe University and Hiroshima University have successfully developed a biomarker that will enable Parkinson’s disease to be rapidly and inexpensively diagnosed from blood serum samples.
Publishing in Springer Nature’s open journal Scientific Reports, the researchers hope that being able to diagnose the disease faster will also lead to the development of new treatment methods – this would be greatly beneficial, especially for aging societies like Japan.
Longevity.Technology: Japan has the fastest growing elderly population in the world and is consequently facing related issues such as the decline in elderly people’s quality of life (QoL) and pressure on the caregiving sector. As people age, their risk of developing various diseases increases – in particular, neurodegenerative diseases such as Parkinson’s disease have a significant impact on the sufferer’s QoL. In addition, Parkinson’s is the second most common neurodegenerative disease in the world, believed to affect around 1~2% of the over 60s population and is predicted to cost the global market US$19.9 billion (including treatment costs) in 2030.
Currently, there is no way of completely curing Parkinson’s disease – this means that early detection is vital in order to stop its progression. In addition, it is predicted that even earlier detection will be important in the future as various pharmaceutical companies are currently working on developing therapeutic drugs for Parkinson’s. There is a pressing need for a simple screening method that puts little burden on the patient, and that is both easy to carry out and inexpensive.
The drug metabolising enzyme Cytochrome P450 not only metabolises drugs but also serves as a catalyst for the oxidation of various substances. It is known that the expression of P450 inside the body changes with the onset of various diseases and this change in expression is thought to affect the quantity and quality of metabolites in the patient’s body that are related to P450.
This research group had previously come up with a ‘P450 inhibition assay’ to easily detect changes in the quality and quantity of P450-related metabolites brought on by the onset of disease. This time, they became the first in the world to successfully apply this method to Parkinson’s disease diagnosis .
Getting a reaction
In the developed assay, 12 different human P450s are each mixed with a serum sample and a fluorescent substrate to cause a reaction – there are differences in quantity and quality of P450-related metabolites in the sera from healthy individuals and patients. These serum metabolites inhibit the P450-mediated oxidation of the fluorescent substrate, and by looking at the inhibition rate related to disease onset-mediated alterations in certain P450s, it is possible to discriminate sera samples from an individual with a specific disease and a healthy subject. P450 reacts with the fluorescent substrate to generate a fluorescent substance when the assay is performed on the sera from healthy individuals; however, the reaction is different when the assay is conducted on the sera from patients and thus the obtained fluorescent values change.
In this way, the P450 fluorescent inhibition assay can be used to determine whether or not a disease is present by detecting these changes – it is a new liquid biopsy technique that didn’t exist until now.
The current study on Parkinson’s disease used the P450 inhibition assay that was independently developed by this research group. Specifically, they carried out the assay on Parkinson’s disease model rats and on human patients with the disease (as well as patients with other neurodegenerative and inflammatory diseases) to evaluate whether or not the assay could be used for Parkinson’s disease diagnosis.
The results revealed that healthy individuals and individuals with Parkinson’s disease could be classified at an accuracy rate of 85~88% for both the model rat and human subjects .
The results of this study have shown that the P450 inhibition assay has the potential to be applied to the diagnosis of Parkinson’s disease. This assay only requires mere 30μ of serum and is a comparatively inexpensive testing method meaning it could be scaled up for widespread Parkinson’s testing.
Next, the researchers plan to conduct clinical performance evaluations on a larger scale, with the aim of working towards the implementation of this testing method.